KDR and neoplasm: We have now addressed these issues by showing: (a) sorafenib induces a major loss of tumor vascularity without inhibiting innate immune cell recruitment, demonstrating that the loss of vascularity per se is not the cause of the innate immune cell inhibition; and (b) monoclonal antibody DC101 – which is highly specific for VEGFR2 – recapitulates the immune response inhibitory effects of the small molecule RTKIs that we reported earlier, indicating that innate immune cell inhibition is not the consequence of RTKI off-target effects.